0 XP   0   0   0

Emmaus Life Sciences Inc










Financial Health of Emmaus Life Sciences Inc




Comparing to competitors in the Biotechnology industry




  Industry Rankings  


Emmaus Life Sciences Inc
Buy, Hold or Sell?

Should you buy, hold or sell Emmaus Life Sciences Inc?

I guess you are interested in Emmaus Life Sciences Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Emmaus Life Sciences Inc

Let's start. I'm going to help you getting a better view of Emmaus Life Sciences Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Emmaus Life Sciences Inc even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Emmaus Life Sciences Inc is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Emmaus Life Sciences Inc. The closing price on 2022-11-30 was $0.388 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Emmaus Life Sciences Inc Daily Candlestick Chart

Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

1.1. Profitability of Emmaus Life Sciences Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Emmaus Life Sciences Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Emmaus Life Sciences Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -7.9% means that $-0.08 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Emmaus Life Sciences Inc:

  • The MRQ is -7.9%. The company is making a loss. -1
  • The TTM is -122.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-7.9%TTM-122.6%+114.6%
TTM-122.6%YOY-45.6%-76.9%
TTM-122.6%5Y-214.4%+91.9%
5Y-214.4%10Y-214.4%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.9%-223.6%+215.7%
TTM-122.6%-281.7%+159.1%
YOY-45.6%-344.8%+299.2%
5Y-214.4%-450.1%+235.7%
10Y-214.4%-541.0%+326.6%
1.1.2. Return on Assets

Shows how efficient Emmaus Life Sciences Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Emmaus Life Sciences Inc to the Biotechnology industry mean.
  • -0.9% Return on Assets means that Emmaus Life Sciences Inc generated $-0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Emmaus Life Sciences Inc:

  • The MRQ is -0.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -8.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-0.9%TTM-8.8%+7.9%
TTM-8.8%YOY-3.9%-4.9%
TTM-8.8%5Y-15.7%+6.8%
5Y-15.7%10Y-15.7%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.9%-9.9%+9.0%
TTM-8.8%-8.9%+0.1%
YOY-3.9%-9.3%+5.4%
5Y-15.7%-11.7%-4.0%
10Y-15.7%-12.7%-3.0%
1.1.3. Return on Equity

Shows how efficient Emmaus Life Sciences Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Emmaus Life Sciences Inc to the Biotechnology industry mean.
  • 0.0% Return on Equity means Emmaus Life Sciences Inc generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Emmaus Life Sciences Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-1.2%+1.2%
5Y-1.2%10Y-1.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--12.0%+12.0%
TTM--11.5%+11.5%
YOY--10.8%+10.8%
5Y-1.2%-14.2%+13.0%
10Y-1.2%-15.2%+14.0%

1.2. Operating Efficiency of Emmaus Life Sciences Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Emmaus Life Sciences Inc is operating .

  • Measures how much profit Emmaus Life Sciences Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Emmaus Life Sciences Inc to the Biotechnology industry mean.
  • An Operating Margin of 23.6% means the company generated $0.24  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Emmaus Life Sciences Inc:

  • The MRQ is 23.6%. The company is operating efficient. +1
  • The TTM is -95.6%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ23.6%TTM-95.6%+119.2%
TTM-95.6%YOY-7.5%-88.1%
TTM-95.6%5Y-39.5%-56.1%
5Y-39.5%10Y-39.5%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ23.6%-207.3%+230.9%
TTM-95.6%-271.0%+175.4%
YOY-7.5%-325.9%+318.4%
5Y-39.5%-454.0%+414.5%
10Y-39.5%-537.1%+497.6%
1.2.2. Operating Ratio

Measures how efficient Emmaus Life Sciences Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.13 means that the operating costs are $1.13 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Emmaus Life Sciences Inc:

  • The MRQ is 1.134. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.766. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.134TTM1.766-0.632
TTM1.766YOY1.117+0.648
TTM1.7665Y1.994-0.228
5Y1.99410Y1.9940.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1342.871-1.737
TTM1.7663.504-1.738
YOY1.1173.604-2.487
5Y1.9945.132-3.138
10Y1.9946.371-4.377

1.3. Liquidity of Emmaus Life Sciences Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Emmaus Life Sciences Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.15 means the company has $0.15 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Emmaus Life Sciences Inc:

  • The MRQ is 0.154. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.182. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.154TTM0.182-0.028
TTM0.182YOY0.742-0.560
TTM0.1825Y1.110-0.928
5Y1.11010Y1.1100.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1545.117-4.963
TTM0.1825.755-5.573
YOY0.7425.854-5.112
5Y1.1106.511-5.401
10Y1.1106.222-5.112
1.3.2. Quick Ratio

Measures if Emmaus Life Sciences Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Emmaus Life Sciences Inc to the Biotechnology industry mean.
  • A Quick Ratio of 0.06 means the company can pay off $0.06 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Emmaus Life Sciences Inc:

  • The MRQ is 0.064. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.063. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.064TTM0.063+0.001
TTM0.063YOY0.906-0.843
TTM0.0635Y0.792-0.729
5Y0.79210Y0.7920.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0644.284-4.220
TTM0.0634.664-4.601
YOY0.9064.787-3.881
5Y0.7925.218-4.426
10Y0.7925.182-4.390

1.4. Solvency of Emmaus Life Sciences Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Emmaus Life Sciences Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Emmaus Life Sciences Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.89 means that Emmaus Life Sciences Inc assets are financed with 189.1% credit (debt) and the remaining percentage (100% - 189.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Emmaus Life Sciences Inc:

  • The MRQ is 1.891. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.614. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ1.891TTM1.614+0.277
TTM1.614YOY1.197+0.416
TTM1.6145Y1.249+0.364
5Y1.24910Y1.2490.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8910.278+1.613
TTM1.6140.277+1.337
YOY1.1970.306+0.891
5Y1.2490.367+0.882
10Y1.2490.403+0.846
1.4.2. Debt to Equity Ratio

Measures if Emmaus Life Sciences Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Emmaus Life Sciences Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Emmaus Life Sciences Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y1.142-1.142
5Y1.14210Y1.1420.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.315-0.315
TTM-0.317-0.317
YOY-0.319-0.319
5Y1.1420.403+0.739
10Y1.1420.462+0.680

2. Market Valuation of Emmaus Life Sciences Inc

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Emmaus Life Sciences Inc generates.

  • Above 15 is considered overpriced but always compare Emmaus Life Sciences Inc to the Biotechnology industry mean.
  • A PE ratio of -21.55 means the investor is paying $-21.55 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Emmaus Life Sciences Inc:

  • The EOD is -49.178. Company is losing money. -2
  • The MRQ is -21.547. Company is losing money. -2
  • The TTM is -17.064. Company is losing money. -2
Trends
Current periodCompared to+/- 
EOD-49.178MRQ-21.547-27.631
MRQ-21.547TTM-17.064-4.483
TTM-17.064YOY-30.988+13.924
TTM-17.0645Y-9.389-7.674
5Y-9.38910Y-9.3890.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-49.178-8.986-40.192
MRQ-21.547-9.792-11.755
TTM-17.064-16.243-0.821
YOY-30.988-20.876-10.112
5Y-9.389-16.665+7.276
10Y-9.389-14.732+5.343
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Emmaus Life Sciences Inc.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Emmaus Life Sciences Inc:

  • The MRQ is -0.991. Very Bad. -2
  • The TTM is 3.757. Seems overpriced? -1
Trends
Current periodCompared to+/- 
MRQ-0.991TTM3.757-4.748
TTM3.757YOY10.304-6.547
TTM3.7575Y7.586-3.829
5Y7.58610Y7.5860.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.991-0.032-0.959
TTM3.7570.004+3.753
YOY10.3040.016+10.288
5Y7.5860.006+7.580
10Y7.5860.003+7.583

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Emmaus Life Sciences Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -0.22 means the investor is paying $-0.22 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Emmaus Life Sciences Inc:

  • The EOD is -0.512. Bad. Book ratio is negative. -2
  • The MRQ is -0.224. Bad. Book ratio is negative. -2
  • The TTM is -1.737. Bad. Book ratio is negative. -2
Trends
Current periodCompared to+/- 
EOD-0.512MRQ-0.224-0.287
MRQ-0.224TTM-1.737+1.513
TTM-1.737YOY-6.239+4.502
TTM-1.7375Y5.198-6.936
5Y5.19810Y5.1980.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.5121.835-2.347
MRQ-0.2242.006-2.230
TTM-1.7372.774-4.511
YOY-6.2393.453-9.692
5Y5.1982.713+2.485
10Y5.1982.402+2.796
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Emmaus Life Sciences Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.060-0.113+90%-0.044-26%-0.042-29%-0.042-29%
Book Value Growth---0.079-0.192+145%-0.145+84%1.953-104%1.953-104%
Book Value Per Share---0.758-0.585-23%-0.243-68%-0.313-59%-0.313-59%
Book Value Per Share Growth---0.079-0.192+145%-0.145+84%1.953-104%1.953-104%
Current Ratio--0.1540.182-16%0.742-79%1.110-86%1.110-86%
Debt To Asset Ratio--1.8911.614+17%1.197+58%1.249+51%1.249+51%
Debt To Equity Ratio----0%-0%1.142-100%1.142-100%
Dividend Per Share----0%-0%-0%-0%
Eps---0.008-0.089+1031%-0.048+514%-0.148+1780%-0.148+1780%
Eps Growth--21.7425.956+265%-2.516+112%1.459+1390%1.459+1390%
Gross Profit Margin--5.2562.415+118%1.000+426%1.314+300%1.314+300%
Net Profit Margin---0.079-1.226+1448%-0.456+476%-2.144+2609%-2.144+2609%
Operating Margin--0.236-0.956+506%-0.075+132%-0.395+267%-0.395+267%
Operating Ratio--1.1341.766-36%1.117+1%1.994-43%1.994-43%
Pb Ratio-0.512-128%-0.224-1.737+675%-6.239+2684%5.198-104%5.198-104%
Pe Ratio-49.178-128%-21.547-17.064-21%-30.988+44%-9.389-56%-9.389-56%
Peg Ratio---0.9913.757-126%10.304-110%7.586-113%7.586-113%
Price Per Share0.388+56%0.1700.823-79%1.490-89%1.348-87%1.348-87%
Price To Total Gains Ratio-6.509-128%-2.852-19.017+567%-14.437+406%-5.629+97%-5.629+97%
Profit Growth--2174.169595.609+265%-251.603+112%185.624+1071%185.624+1071%
Quick Ratio--0.0640.063+2%0.906-93%0.792-92%0.792-92%
Return On Assets---0.009-0.088+854%-0.039+324%-0.157+1590%-0.157+1590%
Return On Equity----0%-0%-0.0120%-0.0120%
Revenue Growth--0.132-0.116+188%-0.004+103%-0.715+642%-0.715+642%
Total Gains Per Share---0.060-0.113+90%-0.044-26%-0.042-29%-0.042-29%
Total Gains Per Share Growth--3.1762.156+47%-0.207+107%-0.204+106%-0.204+106%
Usd Book Value---37589000.000-28993250.000-23%-12051250.000-68%-15525013.056-59%-15525013.056-59%
Usd Book Value Change Per Share---0.060-0.113+90%-0.044-26%-0.042-29%-0.042-29%
Usd Book Value Per Share---0.758-0.585-23%-0.243-68%-0.313-59%-0.313-59%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.008-0.089+1031%-0.048+514%-0.148+1780%-0.148+1780%
Usd Price Per Share0.388+56%0.1700.823-79%1.490-89%1.348-87%1.348-87%
Usd Profit---391000.000-4421750.000+1031%-2401250.000+514%-5771398.278+1376%-5771398.278+1376%
Usd Revenue--4939000.0003870000.000+28%5960500.000-17%4230089.333+17%4230089.333+17%
Usd Total Gains Per Share---0.060-0.113+90%-0.044-26%-0.042-29%-0.042-29%
 EOD+3 -2MRQTTM+24 -7YOY+16 -155Y+19 -1310Y+19 -13

3.2. Fundamental Score

Let's check the fundamental score of Emmaus Life Sciences Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-49.178
Price to Book Ratio (EOD)Between0-1-0.512
Net Profit Margin (MRQ)Greater than0-0.079
Operating Margin (MRQ)Greater than00.236
Quick Ratio (MRQ)Greater than10.064
Current Ratio (MRQ)Greater than10.154
Debt to Asset Ratio (MRQ)Less than11.891
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.009
Total2/10 (20.0%)

3.3. Technical Score

Let's check the technical score of Emmaus Life Sciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5055.150
Ma 20Greater thanMa 500.380
Ma 50Greater thanMa 1000.276
Ma 100Greater thanMa 2000.316
OpenGreater thanClose0.400
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2021-09-302021-12-312022-03-312022-06-302022-09-30
EBIT  -31-6,153-6,1845,276-908-6,515-7,4238,5871,164
EBITDA  -2,222-3,947-6,1695,276-893-6,517-7,4108,6141,204



Latest Balance Sheet

Balance Sheet of 2022-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets42,201
Total Liabilities79,790
Total Stockholder Equity-37,589
 As reported
Total Liabilities 79,790
Total Stockholder Equity+ -37,589
Total Assets = 42,201

Assets

Total Assets42,201
Total Current Assets6,382
Long-term Assets6,382
Total Current Assets
Cash And Cash Equivalents 1,179
Net Receivables 1,491
Inventory 2,739
Other Current Assets 973
Total Current Assets  (as reported)6,382
Total Current Assets  (calculated)6,382
+/-0
Long-term Assets
Property Plant Equipment 3,023
Long Term Investments 32,537
Other Assets 259
Long-term Assets  (as reported)35,819
Long-term Assets  (calculated)35,819
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities41,523
Long-term Liabilities38,267
Total Stockholder Equity-37,589
Total Current Liabilities
Short-term Debt 28,086
Short Long Term Debt 27,433
Accounts payable 11,134
Other Current Liabilities 2,303
Total Current Liabilities  (as reported)41,523
Total Current Liabilities  (calculated)68,956
+/- 27,433
Long-term Liabilities
Capital Lease Obligations 3,417
Other Liabilities 32,122
Long-term Liabilities  (as reported)38,267
Long-term Liabilities  (calculated)35,539
+/- 2,728
Total Stockholder Equity
Common Stock50
Retained Earnings -252,537
Accumulated Other Comprehensive Income -5,905
Other Stockholders Equity 220,803
Total Stockholder Equity (as reported)-37,589
Total Stockholder Equity (calculated)-37,589
+/-0
Other
Capital Stock50
Cash and Short Term Investments 1,179
Common Stock Shares Outstanding 49,312
Liabilities and Stockholders Equity 42,201
Net Debt 33,052
Net Invested Capital -6,775
Net Tangible Assets -37,589
Net Working Capital -35,141
Short Long Term Debt Total 34,231



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-30
> Total Assets 
73,935
84,806
74,555
3,141
4,348
56,482
59,456
0
56,250
59,944
59,456
62,223
63,279
60,057
56,734
51,493
45,989
42,201
42,20145,98951,49356,73460,05763,27962,22359,45659,94456,250059,45656,4824,3483,14174,55584,80673,935
   > Total Current Assets 
72,870
83,675
73,459
66,807
56,649
51,774
41,221
48,238
38,536
40,894
41,221
14,141
13,040
12,474
9,091
6,448
6,586
6,382
6,3826,5866,4489,09112,47413,04014,14141,22140,89438,53648,23841,22151,77456,64966,80773,45983,67572,870
       Cash And Cash Equivalents 
2,169
16,662
17,080
1,203
2,443
13,546
1,769
0
1,032
4,949
1,769
3,759
1,671
2,321
2,279
813
982
1,179
1,1799828132,2792,3211,6713,7591,7694,9491,03201,76913,5462,4431,20317,08016,6622,169
       Short-term Investments 
66,007
61,586
49,343
42,873
32,890
27,643
27,929
0
27,007
0
27,929
0
27,007
0
0
0
0
0
0000027,007027,929027,007027,92927,64332,89042,87349,34361,58666,007
       Net Receivables 
1,702
1,415
1,361
1,760
1,981
1,900
2,150
1,900
1,457
1,726
2,150
2,772
3,359
3,242
1,040
938
1,235
1,491
1,4911,2359381,0403,2423,3592,7722,1501,7261,4571,9002,1501,9001,9811,7601,3611,4151,702
       Inventory 
2,435
3,347
4,705
5,795
5,906
7,491
7,971
8,255
7,863
7,422
7,971
6,740
6,543
6,252
4,392
3,453
3,134
2,739
2,7393,1343,4534,3926,2526,5436,7407,9717,4227,8638,2557,9717,4915,9065,7954,7053,3472,435
       Other Current Assets 
341
346
238
251
0
0
1,402
0
7
25,680
1,402
237
1,467
250
1,380
1,244
1,235
973
9731,2351,2441,3802501,4672371,40225,680701,40200251238346341
   > Long-term Assets 
0
0
0
1,593
1,570
4,708
18,235
0
17,714
19,050
18,235
48,082
50,239
47,583
47,643
45,045
39,403
35,819
35,81939,40345,04547,64347,58350,23948,08218,23519,05017,714018,2354,7081,5701,593000
       Property Plant Equipment 
138
152
152
2,991
145
4,281
151
4,486
4,424
4,275
151
4,056
99
3,739
3,632
3,456
3,170
3,023
3,0233,1703,4563,6323,739994,0561514,2754,4244,4861514,2811452,991152152138
       Goodwill 
0
0
0
1,387
1,387
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000001,3871,387000
       Long Term Investments 
538
572
538
527
0
0
13,325
0
13,005
14,484
15,664
15,790
17,383
17,835
17,616
17,771
16,982
32,537
32,53716,98217,77117,61617,83517,38315,79015,66414,48413,005013,32500527538572538
       Intangible Assets 
60
57
54
88
74
44
0
0
0
0
0
0
0
0
0
0
0
0
000000000000447488545760
       Long-term Assets Other 
0
0
0
30
26
4,708
18,084
0
0
0
18,084
293
32,757
293
26,395
23,818
36,233
32,796
32,79636,23323,81826,39529332,75729318,08400018,0844,7082630000
> Total Liabilities 
103,223
96,351
90,449
2,629
2,665
74,732
70,509
0
70,269
66,309
70,509
74,899
72,654
75,158
78,184
73,792
80,624
79,790
79,79080,62473,79278,18475,15872,65474,89970,50966,30970,269070,50974,7322,6652,62990,44996,351103,223
   > Total Current Liabilities 
41,982
29,961
37,527
53,490
57,251
35,233
32,827
29,060
26,475
23,780
32,827
24,407
20,513
25,026
37,100
34,551
46,076
41,523
41,52346,07634,55137,10025,02620,51324,40732,82723,78026,47529,06032,82735,23357,25153,49037,52729,96141,982
       Short-term Debt 
8,170
14,138
11,253
15,157
28,047
18,007
10,648
0
0
0
10,648
0
1,862
0
22,004
21,256
32,167
28,086
28,08632,16721,25622,00401,862010,64800010,64818,00728,04715,15711,25314,1388,170
       Short Long Term Debt 
8,170
14,138
11,253
15,157
28,047
18,007
14,552
0
12,499
12,277
11,002
13,416
9,367
11,002
21,264
20,518
31,849
27,433
27,43331,84920,51821,26411,0029,36713,41611,00212,27712,499014,55218,00728,04715,15711,25314,1388,170
       Accounts payable 
392
976
937
692
11,455
794
11,691
264
128
352
11,691
100
6,401
66
2,583
2,873
10,718
11,134
11,13410,7182,8732,583666,40110011,69135212826411,69179411,455692937976392
       Other Current Liabilities 
21,652
2,152
5,199
5,217
6,116
5,676
10,488
1,126
2,496
2,728
10,488
12,239
12,250
13,066
12,513
10,422
3,191
2,303
2,3033,19110,42212,51313,06612,25012,23910,4882,7282,4961,12610,4885,6766,1165,2175,1992,15221,652
   > Long-term Liabilities 
0
0
0
728
739
39,499
37,682
0
43,794
42,529
37,682
50,492
52,141
50,132
41,084
39,241
34,548
38,267
38,26734,54839,24141,08450,13252,14150,49237,68242,52943,794037,68239,499739728000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
3,150
0
12,526
0
0
0
0
0
0000012,52603,1500000000000
       Capital Lease Obligations 
0
0
0
3
2
4,558
4,923
0
4,825
4,688
4,613
4,485
4,328
4,167
4,001
3,822
3,572
3,417
3,4173,5723,8224,0014,1674,3284,4854,6134,6884,82504,9234,55823000
       Long-term Liabilities Other 
0
0
0
0
0
34,556
37,682
0
26,434
25,436
37,682
24,473
39,615
22,275
23,173
21,507
21,694
22,122
22,12221,69421,50723,17322,27539,61524,47337,68225,43626,434037,68234,55600000
> Total Stockholder Equity
-29,289
-11,545
-15,797
2,025
3,801
-17,525
-11,053
0
-14,019
-6,365
-11,053
-12,676
-9,375
-15,101
-21,450
-22,299
-34,635
-37,589
-37,589-34,635-22,299-21,450-15,101-9,375-12,676-11,053-6,365-14,0190-11,053-17,5253,8012,025-15,797-11,545-29,289
   Common Stock
34
36
36
36
-36,439
47
48
49
49
49
48
49
49
49
49
49
50
50
50504949494949484949494847-36,43936363634
   Retained Earnings Total Equity00000-231,2530-226,229000-226,229000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-255
433
-3,339
-5,905
-5,905-3,339433-25500000000000000
   Capital Surplus 
0
0
0
0
0
0
215,207
0
0
0
215,207
0
219,924
0
0
0
0
0
00000219,9240215,207000215,207000000
   Treasury Stock000000000000000000
   Other Stockholders Equity 
-70
-75
-69
-62
0
-51
-79
-18
-51
-86
-79
1,367
1,905
-763
220,022
220,027
220,800
220,803
220,803220,800220,027220,022-7631,9051,367-79-86-51-18-79-510-62-69-75-70



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue20,610
Cost of Revenue-3,312
Gross Profit17,29817,298
 
Operating Income (+$)
Gross Profit17,298
Operating Expense-23,426
Operating Income-6,128-6,128
 
Operating Expense (+$)
Research Development4,110
Selling General Administrative13,438
Selling And Marketing Expenses5,878
Operating Expense23,42623,426
 
Net Interest Income (+$)
Interest Income761
Interest Expense-3,101
Net Interest Income-2,340-2,340
 
Pretax Income (+$)
Operating Income-6,128
Net Interest Income-2,340
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-15,9213,665
EBIT - interestExpense = -15,921
-15,921
-12,845
Interest Expense3,101
Earnings Before Interest and Taxes (ebit)-12,820-12,820
Earnings Before Interest and Taxes (ebitda)-12,761
 
After tax Income (+$)
Income Before Tax-15,921
Tax Provision-25
Net Income From Continuing Ops-15,946-15,946
Net Income-15,946
Net Income Applicable To Common Shares-15,946
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses26,738
Total Other Income/Expenses Net-9,7932,340
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
DOM.LSE
now

I found you a Overbought RSI (Relative Strength Index) on the daily chart of DOM.LSE.

DOM.LSE Daily Candlestick Chart
DNLM.LSE
now

I found you a Overbought RSI (Relative Strength Index) on the daily chart of DNLM.LSE.

DNLM.LSE Daily Candlestick Chart
FCRM.LSE
6 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of FCRM.LSE.

FCRM.LSE Daily Candlestick Chart
XLPS.LSE
9 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of XLPS.LSE.

XLPS.LSE Daily Candlestick Chart
PHGP.LSE
11 minutes ago

I found you a Death Cross on the daily chart of PHGP.LSE.

PHGP.LSE Daily Candlestick Chart
EMLI.LSE
12 minutes ago

I found you a Golden Cross on the daily chart of EMLI.LSE.

EMLI.LSE Daily Candlestick Chart
SLVR.LSE
13 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of SLVR.LSE.

SLVR.LSE Daily Candlestick Chart
GBAL.TO
13 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of GBAL.TO.

GBAL.TO Daily Candlestick Chart
ACC.BSE
21 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ACC.BSE.

ACC.BSE Daily Candlestick Chart
VRL.BSE
30 minutes ago

I found you a Golden Cross on the daily chart of VRL.BSE.

VRL.BSE Daily Candlestick Chart
CANDOUR.BSE
30 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CANDOUR.BSE.

CANDOUR.BSE Daily Candlestick Chart
VMUK.LSE
42 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of VMUK.LSE.

VMUK.LSE Daily Candlestick Chart
YGEN.LSE
42 minutes ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of YGEN.LSE.

YGEN.LSE Daily Candlestick Chart
GROC.LSE
42 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of GROC.LSE.

GROC.LSE Daily Candlestick Chart
HMAD.LSE
43 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of HMAD.LSE.

HMAD.LSE Daily Candlestick Chart
XSLR.LSE
44 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of XSLR.LSE.

XSLR.LSE Daily Candlestick Chart
0HA0.LSE
44 minutes ago

I found you a Golden Cross on the daily chart of 0HA0.LSE.

0HA0.LSE Daily Candlestick Chart
APAX.LSE
45 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of APAX.LSE.

APAX.LSE Daily Candlestick Chart
PDL.LSE
45 minutes ago

I found you a Death Cross on the daily chart of PDL.LSE.

PDL.LSE Daily Candlestick Chart
XZEZ.LSE
47 minutes ago

I found you a Golden Cross on the daily chart of XZEZ.LSE.

XZEZ.LSE Daily Candlestick Chart
XZBD.LSE
47 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of XZBD.LSE.

XZBD.LSE Daily Candlestick Chart
VGPA.LSE
47 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of VGPA.LSE.

VGPA.LSE Daily Candlestick Chart
HXEM.TO
47 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of HXEM.TO.

HXEM.TO Daily Candlestick Chart
4I1.XETRA
47 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of 4I1.XETRA.

4I1.XETRA Daily Candlestick Chart